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ABSTRACT  
Importance: Children with neurodevelopmental disorders have a higher prevalence of sleep 
disturbances. Currently there is variation in the melatonin use, hence an up to date systematic review is 
indicated to summarize the current available evidence. 
Objectives: To determine the efficacy and safety of melatonin as therapy for sleep problems in 
children with neurodevelopmental disorders.   
Data sources and study selections: PubMed, Embase, CINAHL, and the Cochrane Central Register of 
Controlled Trials from inception up to March 2017. Two reviewers performed data assessment and 
extraction. We assessed randomized controlled trials that compared melatonin with placebo or other 
intervention for the management of sleep disorders in children (<18 years) with neurodevelopmental 
disorders.  
Data extraction and synthesis: We identified 3262 citations, and included 13 studies in this meta-
analysis.  
Main outcomes: Included total sleep time, sleep onset latency, frequency of nocturnal awakenings, 
and adverse events.  
Results: Thirteen RCTs (n=682), met the inclusion criteria. A meta-analysis of 9 studies (n=541) 
showed that melatonin significantly improved total sleep time compared with placebo (MD 48.26 min, 
95% CI: 36.78 to 59.73, I2 =31%). In 11 studies (n= 581), sleep onset latency improved significantly 
with melatonin use (MD= -28.97, 95% CI -39.78 to -18.17).  No difference was noted in the frequency 
of nocturnal awakenings (MD= -0.49, 95% CI -1.71 to 0.73).  No medication-related serious adverse 
event was reported.  
Conclusion: Melatonin appeared safe and effective for improving sleep in the studied children. The 
overall quality of the evidence is limited due to heterogeneity and inconsistency. Further research is 
needed. 
Keywords: Melatonin, Developmental Disorders, Sleep disorders, Systematic Reviews, Meta-analysis, 
Randomized controlled trials. 
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What is already known on this subject 
• Children with neurodevelopmental disorders have a higher prevalence of sleep disturbances. 
• Previous studies suggested that melatonin might be beneficial for improving sleep disorders in 
these children. 
What this study adds  
• Evidence from this comprehensive systematic review and meta-analysis shows that melatonin 
may be effective for improving total sleep time and sleep latency in children with 
neurodevelopmental disorders. 
• No serious adverse events were associated with the use of melatonin in these children. 
• The overall quality of the evidence is limited due to heterogeneity and inconsistency. 
• Further well designed, larger randomised controlled trials are needed to further conclude on 
these findings 
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INTRODUCTION  
Children with neurodevelopmental disorders have a higher prevalence of sleep disturbances than their 
unaffected peers and this could potentially have a negative effect on learning and behaviour.[1] Recent 
studies suggest that the prevalence of sleep disorders in children with developmental disabilities ranges 
from 25% to 86%.[2] Melatonin is a neurohormone, well known for its effect on the regulation of the 
circadian sleep-wake rhythm. In physiologic conditions, it has a plasma concentration that follows a 
circadian rhythm, with low levels during the day and high levels at night. In humans, the peak secretion 
typically occurs at around 2 am, which explains the name “darkness hormone”.[3] Melatonin appears 
to have other multiple actions other than sleep regulation. It has potent antioxidant action,[4] protects 
the organism from carcinogenesis and has an immune modulation effect.[5] Studies of melatonin 
production in children with sleep disorders were often limited by small sample sizes and were not 
entirely consistent, but reported abnormalities in melatonin production strongly indicate that nocturnal 
secretion of melatonin is often low in children with neurodisability and those with autistic spectrum 
disorders.[6] 
 It has been suggested from previous studies that melatonin might be effective on improving total sleep 
time,[7, 8]  time to sleep onset “sleep latency”,[8, 9, 10]  and number of awakenings.[7] 
Many children with developmental disorders, such as autistic spectrum disorder, attention-
deficit/hyperactivity disorder and intellectual disability, experience sleep disturbances and may 
potentially benefit from melatonin treatment.[11] In five studies assessed by Hollway et al, information 
was given on parental perception of the effect of melatonin on their family life.[2] Parents and 
caregivers reported that they spent less time and effort in getting their child to stay in bed, while 
daytime behaviour and alertness on the part of the child also improved.  
The results of a systematic review conducted by Appleton et al in 2004 suggested that melatonin might 
be effective in reducing sleep latency in children with neurodevelopmental disabilities.[10] Since that 
review, there have been a number of clinical trials that have investigated the effect of melatonin on the 
sleep pattern in children with neurodevelopmental disorders.  Currently in the UK, there is variation in 
the guidance on the use of melatonin between clinical commissioning groups. An up to date systematic 
review using the Cochrane Collaboration format is indicated to summarise the current evidence on the 
use of melatonin compared with placebo for the treatment of sleep disorders in children with 
neurodevelopmental disorders. This review evaluated the effect of melatonin on total sleep time, sleep 
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onset latency, frequency of nocturnal awakening, early-morning awakening time, parental perception 
of the effect of melatonin treatment on their child’s behaviour, and adverse events. 
 
 MATERIAL AND METHODS  
Study selection and search strategy  
This systematic review was conducted according to the Preferred Reporting Items for Systematic 
Reviews and meta-analysis (PRISMA) criteria. A study protocol was conducted and is available online 
under this registration number: PROSPERO CRD42015024170. 
We searched the following databases from inception to March 2017, that was then updated January 
2018: PubMed, Embase, CINAHL and the Cochrane Central Register of Controlled Trials 
(CENTRAL). Reference lists from retrieved articles were inspected to identify additional citations that 
may have been missed by the electronic searches. We also searched for current unpublished ongoing 
clinical trials on the following websites: www.clinicaltrials.gov and www.controlled-trials.com. The 
search strategy included these terms: Melatonin (All Fields) AND (Neurodevelopmental disorder* OR 
Neurodevelopmental disabilit* OR Developmental delay* OR Behaviour disorder* OR Attention 
deficit hyperactivity disorder OR ADHD OR Autistic spectrum disorder or autism or Asperger 
syndrome OR Communication disorder* OR Sleep OR Sleep disorder* OR Insomnia OR Sleep quality 
OR Sleep difficult*OR Sleep disturbance* OR Sleep problem*) (see Appendix 1). 
We applied no language restriction, and English translation was to be considered for relevant studies 
when needed.  
Study characteristics  
We included randomized controlled trials (RCTs) that compared melatonin to either placebo or any 
other intervention. The unit of analysis was the participating child that needed melatonin for sleep 
disorder. Cluster randomized trials were not included.  
Participants were patients below 18 years of age with neurodevelopmental and sleep disorders. 
Interventions of the included trials included the therapeutic use of melatonin for sleep disorder. 
Melatonin should have been compared with placebo or any other intervention.   
The primary outcome measure was total sleep time. Secondary outcome measures included: sleep onset 
latency, frequency of nocturnal awakening and early-morning awakening time, parental perception of 
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the effect of melatonin treatment on their child’s behaviour, quality of life for both children and 
families and adverse events. 
Data extraction and quality assessment  
Using the above search strategy, papers that appeared to be potentially relevant were identified by two 
reviewers (IA, MG). We obtained full-text versions of all studies that were included in the review for 
assessment. We used a data extraction form that included risk of bias assessment, demographic 
information, methodology, intervention details, and reported outcomes. Two reviewers (IA, MG) 
extracted the data independently from each eligible study and compared the extracted data for any 
differences, which was resolved by discussion. Any disagreement was discussed and where necessary 
resolved by consultation with the third author (AA). We used the Cochrane Collaboration’s Review 
Manager (RevMan, version 5.3) for data processing and analysis. 
The criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions were used to 
assess the risk of bias.[12] Two reviewers (IA, MG) independently assessed the risk of bias for each 
study. Any disagreement was resolved by discussion or by involving a third reviewer (AA). We 
assessed the risk of bias according to the following criteria: random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective outcome reporting and other bias.[12] We graded each potential risk of bias as 
being at low, high or unclear risk. We contacted the authors of published studies for further 
clarification or to provide additional information when required.  
Statistical analysis 
We used the Cochrane Collaboration’s Review Manager (RevMan) software (version 5.3) for statistical 
analysis. We performed meta-analysis for the outcomes that were amenable for pooled data synthesis 
using the random-effects model. We calculated the mean difference (MD) and corresponding 95% 
confidence intervals (CIs) for continuous outcomes measured using the same units. Narrative 
description was used to synthesize trial outcome data where data cannot be combined or significant 
heterogeneity exists 
Assessment of Subgroups and Statistical Heterogeneity  
Heterogeneity was assessed by the visual inspection of the forest plots and was tested using the I
2 
statistic, in which I
2
>50% indicated significant heterogeneity.[13] 
Planned subgroup analyses were based on: a) type of neurodevelopmental disability, b) dosage of 
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melatonin, c) duration of treatment, d) age and e) the method used for sleep times measurements. We 
used sensitivity analyses to explore the impact of including only non-crossover studies in the analysis. 
All analyses were also subjected to fixed-effects model analysis to explore differences that would 
indicate heterogeneity. We used the GRADE system [14] to assess the quality of the body of evidence 
associated with specific outcomes (total sleep time, sleep onset latency, frequency of nocturnal 
awakening, early-morning awakening time). A funnel plot was to be used to investigate the potential of 
reporting and publication biases when at least 10 studies contributed to an outcome.  
 
RESULTS 
Identifying studies and quality assessment  
We identified 3262 citations from the database searches of the pre-specified websites. Seven more 
citations were identified from searching other resources. 3217 studies were excluded from screening of 
titles and abstracts. We screened full paper copies of 52 citations that were potentially eligible for 
inclusion in the review. From the full texts, seventeen studies were excluded as duplicates, fifteen 
studies were excluded as non-RCTs, three studies included adults’ data, two studies were excluded 
because melatonin was not used for sleep disorder and two studies assessed children with no 
neurodevelopmental disorders. We included 13 studies [15-26] involving a total of 682 children in this 
systematic review. A flow chart detailing the studies’ selection process is shown in Figure 1. 
Characteristics of eligible studies  
All the included studies were prospective RCTs (see Table 1). Participants were children below18 
years of age that had both neurodevelopmental and sleep disorders. The studies were conducted in 
Europe, North America and Iran. Eight studies were crossover RCTs.[17, 18, 20, 22, 24-27] The 
enrolled children were described in the primary studies to have the following neurodevelopmental 
disabilities: neurodevelopmental disorder,[15, 17, 24] autistic spectrum disorders,[16, 18, 19, 27] 
attention-deficit hyperactivity disorder (ADHD),[21, 23, 25] Fragile X Syndrome,[26]  Rett syndrome 
[20]  and mental retardation.[22] Sleep data was recorded either by using sleep diaries (7 studies),[ 17, 
18, 19, 21, 22, 25, 27] using actigraph (4 studies),[19, 20, 23, 24, 26]  or both (2 studies).[15, 16] The 
melatonin used was fast release melatonin in 10 studies,[15, 17, 18, 20-23, 25-27] and two studies used 
a combination of the slow and fast melatonin preparations.[16, 24] . One further study used slow release 
melatonin [19]. The dosages used ranged from 0.1 -12 mg. Escalating dose of melatonin according to 
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response was used in three of the included studies.[15, 19, 27]  Duration of melatonin treatment ranged 
from one  to 13 weeks. 
Study ID  Countr
y of the 
study  
Type of 
participants’ 
disorder  
Numbe
r of 
Childr
en (n) 
Age group  Type of 
melatonin and 
doses  
Sleep 
diary or  
actigraph 
record 
Appleton 
2012.15 
UK Neurodevelopment
al disorder  
 n=110  3-15 years 
and 8 
months  
0.5-12 mg slow 
release 
Both diary 
and 
Actigraph  
Cortesi 
2012.16 
Italy Autism spectrum 
disorders 
n=134  4-10 years   1-mg fast-
release and 2-
mg controlled-
release  
Both diary 
and 
Actigraph  
Dodge 
2001.17 
USA Moderate to severe 
developmental 
disability 
n=20  1-12 years  5 mg fast 
release 
melatonin  
Sleep 
diary  
Garstang 
2006.18 
UK Autistic spectrum 
disorder  
n=11  4-16 years  5 mg fast 
release 
melatonin 
Sleep 
diary  
Gringras 
2017. 19 
USA & 
Europe 
Autistic spectrum 
disorder 
n=125 2-17.5 years 2-5 mg slow 
release 
melatonin 
Sleep 
diary 
McArthur 
1998.20 
USA Girls with Rett 
syndrome  
n=9  4-17 years  2.5 -7.5 mg 
fast release 
melatonin 
Actigraph 
Mostafavi 
2012.21 
Iran  Attention-deficit 
hyperactivity 
disorder (ADHD).  
n=50  7-12 years 3 or 6 mg fast 
release 
melatonin 
Sleep 
diary  
Niederhofer 
2003.22 
Austria Mental retardation  n=20  14-18 Years  0.1-0.3 mg fast 
release 
melatonin 
Sleep 
diary  
Van der 
Heijden 
2007.23 
Netherl
and 
Attention-deficit 
hyperactivity 
disorder (ADHD). 
n=105  6-12 years  3 or 6 mg fast 
release 
melatonin 
Actigraph 
Wasdell 
2008.24 
Canada Neurodevelopment
al disabilities 
n=50  2-18 years  1 mg fast, 4 mg 
sustained 
release 
melatonin  
Actigraph  
Weiss 
2006.25 
Canada Adolescents With 
ADHD 
n=19  6-14 years  5 mg fast 
release 
melatonin 
Sleep 
diary  
Wirojanan 
2009.26 
Canada Autism, Fragile X 
Syndrome, or 
Autism and Fragile 
X Syndrome 
n=12  2-15.3 years  3 mg fast 
release 
melatonin 
Actigraph  
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Wright 
2011.27 
UK Autism Spectrum 
Conditions 
n=17  4-16 years  2-10 fast 
release 
melatonin 
Sleep 
diary  
 
Table 1. Characteristics of included studies 
 
Risk of bias  
The risk of bias assessment across all 13 included studies is shown in Figure 2 and Figure 3. Eight  
studies gave sufficient details about randomization and allocation to be assessed as having a low risk of 
selection bias.[15, 16, 19, 21, 23-25, 27]  Only one study was classified as high risk for random 
sequence generation.[26] Eleven studies were classified as low risk for participants and personnel 
blinding.[15-17, 20-27] Six studies adopted good measures to reduce the risk of bias in outcome 
assessment by using actigraph to measure the sleep times.[15, 16, 21, 23, 24, 26]  In 10 studies, there 
were enough outcomes assessments data to be classified as low risk,[16, 19-27] and all the 13 studies 
included in the review were of low risk for reporting bias.  
 
Effect of melatonin  
Total sleep time  
Nine studies (n=541) provided sufficient data for this outcome and these were included in the data 
synthesis.[15-19, 23, 24, 26, 27 ] There was a statistically significant higher total sleep time in the 
melatonin group compared with the placebo group (MD= 48.26 minutes, 95% CI 36.79 to 59.73) 
(Figure 4). There was mild heterogeneity among the studies (I
2
=31%). A sensitivity analysis using the 
fixed effects model made no significant difference to the results.  Analysing only the non-crossover 
RCTs also made no significant difference to the results: melatonin remained superior in improving total 
sleep time (MD=51.26, 95% CI 42.56 to 59.96). 
Sleep onset latency  
Sleep onset latency was defined as the time taken to fall asleep by most of the studies’ authors.  All the 
13 included studies assessed this outcome, however we included only 11 studies (n=581) that provided 
sufficient data in a suitable format to be included in the data synthesis.[15-20, 23-27]   The pooled data 
synthesis showed that sleep onset latency is significantly improved by the use of melatonin (MD= -
28.97, 95% CI -39.78 to -18.17) (Figure 5). There was severe heterogeneity among the included 
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individual studies (I
2
=82%) (Figure 5). A funnel plot for this outcome showed asymmetry of the 
studies’ distribution. This would indicate under reporting of smaller studies (Figure 6). 
 
 
Frequency of nocturnal awakening  
The frequency of the times that participants got awake after starting sleep was measured and data were 
suitable for meta-analysis in 6 studies (n=277).[16-18, 24, 25, 27] 
The results showed that there was no significant difference between participants receiving melatonin or 
placebo (MD= -0.49, 95% CI -1.71 to 0.73). There was severe heterogeneity among the included 
individual studies (I
2
=95%) (Figure 7). 
Adverse events  
Eleven studies reported on melatonin adverse events.[15-19, 21, 22, 24-27]  There was no reported 
difference from the primary studies between melatonin and placebo groups, but there was not suitable 
data to allow meta-analysis on this outcome.  
Child’s behaviour  
The parental perception of the effect of melatonin treatment on their child’s behaviour for both children 
and families was reported in seven studies.[15, 18, 21, 23-25, 27]  The direction of changes in 
children’s behaviour favoured melatonin in four of these studies,[15, 18, 24, 27] and parents felt their 
children behaviour improved with melatonin treatment compared with placebo.  However, studies that 
assessed children with ADHD reported no differences in behaviour between children received 
melatonin and those who received placebo treatment.[21, 23, 25] 
Other outcomes  
There wasn’t enough data to allow a report on early-morning awakening time.  
Subgroup analysis  
Outcome: total sleep time  
Subgroup analysis was done for the outcome total sleep time based on the type of neurodevelopmental 
disorders. Only studies that assessed children with neurodisabilities,[15, 17, 24]  and autistic spectrum 
disorders[16, 18, 19, 27] could be grouped for data synthesis, and the pooled estimate showed a 
significantly higher total sleep time in the participants who received melatonin compared with placebo, 
in both neurodisabilities group (MD= 27.91, 95% CI 4.23 to 51.60) and autistic spectrum disorder 
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group (MD= 61.30, 95% CI 50.48 to 72.13) (Figure 8).  
Outcome: Sleep onset latency 
There was heterogeneity among the included studies noted on the initial analysis. This was improved 
when subgroup analysis was done according to neurodevelopmental disabilities diagnoses that is stated 
by the primary studies (MD= -26.09, 95% CI -32.13 to – 20.05) (I
2
=0 %) (Figure 9). 
Subgroup analyses on the dosage of melatonin, duration of treatment, and age were not feasible as 
there was no suitable available data. 
 
GRADE Assessment  
The GRADE quality of evidence for the outcomes: total sleep times, sleep onset latency and frequency 
of nocturnal awakening were downgraded to moderate because of inconsistency and heterogeneity of 
the studies.  
DISCUSSION  
Summary of the findings  
The results of this systematic review and meta-analysis show that melatonin significantly improves 
total sleep time by about 48 minutes when used for children with neurodevelopmental disabilities. 
Children with autistic spectrum disorder showed an improvement in their sleep times by a mean of 61 
minutes more sleep with melatonin treatment. Sleep onset latency was improved by a mean of about 29 
minutes. The frequency of night-time awakening was not different between patients who received 
melatonin and those who received placebo. There was heterogeneity between the studies so it is 
difficult to conclude on these results. Getting to sleep earlier by around 30 minutes and having an extra 
48 minutes of sleep might be statistically significant but its clinical significance needs to be evaluated 
further. Parents and caregivers reported that melatonin improved the rating on health issues and 
improved sleep and family stress.[29] 
The doses of melatonin used varied between the primary studies and no consistency was noted. The 
dosages used ranged from 0.1 -12 mg. Escalating dose of melatonin according to response was used in 
two of the included studies.[15, 19, 27]  Duration of treatment ranged from 1 week to 13 weeks with no 
consistent pattern noted among the studies. Both subjective (sleep diary), and objective (Actigraph) 
measures of sleep were used for assessment of sleep among the primary studies. With sleep diary, 
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periods could be missed when a child is awake and not disturbing the family.[15] Actigraphy might 
pick up restless sleep and artefact movements as being awake.[15] However actigraphy has become an 
important assessment tool in sleep research and is considered a sensitive and objective tool of 
assessment in clinical efficacy of interventions in sleep medicine.[30] 
Most of the included studies on this meta-analysis (eight out of thirteen) were crossover RCTs. The 
washout periods between melatonin and placebo treatment groups varied between studies. Only one 
study had no washout period,[27] and the remainder of the crossover studies had 3-7 days as a washout 
period. Some authors believed that there could be a carry on effect of melatonin on sleep parameters 
and circadian rhythm.[15, 29, 31] A recent systematic review on the pharmacokinetics of melatonin 
showed that the maximum concentration of melatonin after supplementation would be reached after 
approximately 50 min with oral immediate-release formulations.[31] The elimination half-life of both 
oral and intravenous melatonin was about 45 min.  Kunz et al, in a study involving 14 adults, showed 
that exogenous melatonin appeared to normalize circadian variation in human physiology.[32] This 
effect outlasted the period of melatonin administration and diminished only slowly over time. Even if 
this carry-over observation might have influenced the results, it is unlikely to have affected the validity 
of the conclusion of the meta-analysis.[29] 
The results of this systematic review are similar to previous systematic reviews with comparable 
improvements in sleep times and sleep latency when melatonin was used for children with various 
neurodevelopmental disorders.[10, 28, 29]   
There are some potential limitations of the current study. Some of the included studies had modest 
sample sizes. This could represent difficulties in recruitment of patients. There were some differences 
in the detailed study designs such as the different doses of melatonin used by the primary studies. This 
heterogeneity could have had an impact on the overall results.  
Implications for Policy and Practice 
There are variations in current practice and guidelines on the use of melatonin as an adjunct therapy to 
enhance sleep in children with neurodevelopmental disabilities. The evidence from this study on the 
use of melatonin in this group of children would help guide current practice and recommendations for 
future research. Furthermore, no significant adverse events of melatonin were reported by the primary 
studies.  
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Implications for Research  
Using the GRADE criteria the overall quality of the evidence was judged to be moderate. Therefore the 
strength of our conclusions is limited. Higher quality, adequately powered parallel RCTs investigating 
the efficacy and safety of melatonin for improving sleep disorders in children with neurodevelopmental 
disorders is warranted.  
 
CONCLUSIONS 
In conclusion, the results of this study suggest that melatonin improves total sleep time and sleep onset 
latency with less disturbed night sleep in children with neurodevelopmental disorders. This conclusion 
is limited by heterogeneity and small sample sizes in the primary studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
FOOTNOTES 
Competing interests: All authors have completed the ICMJE uniform disclosure form at 
www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted 
work; no financial relationships with any organisations that might have an interest in the submitted 
work in the previous three years; no other relationships or activities that could appear to have 
influenced the submitted work. 
Contribution: IA, AA conceived the systematic review aims and design. IA, MG contributed to the 
systematic review data assessment, extraction. IA performed data analysis and drafted the manuscript. 
IA, MG, AA performed interpretation of the results, review of the manuscript and approval of 
submitted version of the review. 
Funding: None. 
Data sharing statement: Data extraction form and protocol available by request to 
ibtihalsa@hotmail.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
REFERENCES: 
1. Piazza C, Fisher W, Kahng S. Sleep patterns in children and young adults with mental 
retardation and severe behavior disorders. Dev Med Child Neurol. 1996; 38 (4):335-344. 
 
2. Hollway, J.A., Aman, M.G. Pharmacological treatment of sleep disturbance in developmental 
disabilities. A review of the literature. Res Dev Disabil. 2011; 32 (3):939–62. 
3. Tordjman S, Najjar I, Bellissant E, et al. Advances in the Research of Melatonin in Autism 
Spectrum Disorders. Literature Review and New Perspectives. Int. J. Mol. Sci. 
2013;14(10):20508-20542. 
4. Leon J, Acuña-Castroviejo D, Sainz RM, et al. Melatonin and mitochondrial function. Life 
Sci. 2004;75(7):765-90. 
5. Srinivasan V, Spence DW, Pandi-Perumal, et al. Therapeutic actions of melatonin in cancer: 
possible mechanisms. Integr Cancer Ther.2008;7(3):189-203. 
6. Kostoglou-Athanassiou I. Therapeutic application of melatonin. Ther Adv Endocrinol Metab. 
2013;4(1):13–24. 
7. Camfield, P., Gordon, K., Dooley J, et al. Melatonin appears ineffective in children with 
intellectual deficits and fragmented sleep: six ‘N of 1’ trials. J Child Neurol. 1996;11:341–
343.  
 
8. Bendz LM, Scates AC. Melatonin treatment for insomnia in pediatric patients with attention-
deficit/hyperactivity disorder. Ann Pharmacother. 2010;44(1): 185-191.  
 
9. Jan MMS. Melatonin for the treatment of handicapped children with severe sleep disorder. 
Pediatr Neurol.2000; 23:229-232.  
 
10. Phillips L, Appleton R. Systematic review of melatonin treatment in children with 
neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol. 2004;46:771–
775. 
 
11. Bruni O, Alonso-Alconada D, Besag F, et al. Current role of melatonin in pediatric neurology: 
clinical recommendations. Eur J Paediatr Neurol. 2015; 19(2):122-133. 
 
12. Higgins T, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from 
www.cochrane-handbook.org.  
 
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 
2003;327(7414):557–560. 
 
14. Guyatt GH, Oxman AD, Kunz R, et al. What is “quality of evidence” and why is it important 
to clinicians? BMJ. 2008;336:995–998.  
 
15. Appleton RE, Jones AP, Gamble C, et al. The use of MElatonin in children with 
neurodevelopmental disorders and impaired sleep: a randomized, double-blind, placebo-
controlled, parallel study (MENDS). Health Technol Assess. 2012;16: i-239.  
 
16. Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined 
with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum 
disorders: a randomized placebo-controlled trial. J Sleep Res. 2012 Dec;21(6):700-709. DOI: 
10.1111/j.1365-2869.2012.01021.x 
 
17.  Dodge NN, Wilson GA. Melatonin for the treatment of sleep disorders in children with 
developmental disabilities. J Child Neurol. 2001;16:581-584. 
 
 16 
18. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic 
spectrum disorders and sleep problems. Child Care Health Dev. 2006(5);32:585-589. 
 
19. Gringras P, Nir T, Breddy J, et al. Efficacy and Safety of Pediatric Prolonged-Release 
Melatonin for Insomnia in Children With Autism Spectrum Disorder. J Am Acad Child 
Adolesc Psychiatry 2017;56(11):948–957.  
 
18.20. McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin 
treatment. Dev Med Child Neurol. 1998;409(3):186-192. 
 
19.21. Mohammadi MR, Mostafavi SA, Keshavarz SA, et al. Melatonin effects in methylphenidate 
treated children with attention deficit hyperactivity disorder: a randomized double blind 
clinical trial. Iran J Psychiatry. 2012; 7(2):87-92 
 
20.22. Niederhofer H, Staffen W, Mair A, et al. Brief report: melatonin facilitates sleep in individuals 
with mental retardation and insomnia. J Autism Dev Disord. 2003;33(4):469-72. 
21.23. Van der Heijden KB, Smits MG, Van Someren, et al. Effect of Melatonin on Sleep, Behavior, 
and Cognition in ADHD and Chronic Sleep-Onset Insomnia. J Am Acad Child Adolesc 
Psychiatry. 2007;46(2):233-41.  
 
22.24. Wasdell M, Jan J, Bomben M, et al. A randomized, placebo-controlled trial of controlled 
release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance 
in children with neurodevelopmental disabilities. Pineal Res. 2008;44(1):57–64. 
 
23.25. Weiss MD, Wasdell MB, Bomben MM, et al. Sleep Hygiene and Melatonin Treatment for 
Children and Adolescents With ADHD and Initial Insomnia. J Am Acad Child Adolesc 
Psychiatry. 2006; 45(5): 512-9.  
 
24.26. Wirojanan J, Jacquemont S, Diaz R, et al. The Efficacy of Melatonin for Sleep Problems in 
Children with Autism, Fragile X Syndrome, or Autism and Fragile X Syndrome. J Clin Sleep 
Med. 2009;5(2):145-50. 
 
25.27. Wright B, Sims D, Smart S, et al. Melatonin Versus Placebo in Children with Autism 
Spectrum Conditions and Severe Sleep Problems Not Amenable  to Behaviour Management 
Strategies: A Randomized Controlled Crossover Trial. J Autism Dev Disord. 2011;41(2):175–
84.  
 
26.28. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and 
meta-analysis. Dev Med Child Neurol. 2011;53(9):783–92.  
 
27.29. Braam W, Smits MG, Didden R, et al. Exogenous melatonin for sleep problems in individuals 
with intellectual disability: a meta-analysis. Dev Med Child Neurol. 2009;51(5):340–9.  
   
28.30. Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev 
2011;15(4):259–67.  
29.31. Harpsøe NG, Andersen LP, Gögenur I, et al. Clinical pharmacokinetics of melatonin: a 
systematic review. Eur J Clin Pharmacol. 2015;71(8):901-9.  
 
30.32. Kunz D, Mahlberg R, Müller C, et al. Melatonin in patients with reduced REM sleep duration: 
two randomized controlled trials. J Clin Endocrinol Metab.2004;89(1):128–34. 
 
 
 
 
 
 
 
 17 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
 
 
I. Figure 1: Study flow (PRISMA) diagram 
II. Figure 2: Risk of bias graph 
III. Figure 3: Risk of bias summary 
IV. Figure 4: Total sleep times 
V. Figure 5: Sleep onset latency 
VI. Figure 6: Funnel plot of the outcome: Sleep onset latency 
VII. Figure 7: Frequency of nocturnal awakening; subgroups: actigraph and sleep diary 
measurements 
VIII. Figure 8: Total sleep time. Subgroups: children with neurodisabilities and autistic 
spectrum disorders 
IX. Figure 9: Sleep onset latency. Subgroups: children with neurodisabilities, ADHD and 
autistic spectrum disorders 
 
 
 
 
 
  
 18 
SUPPLEMENTS  
 
 
i. APPENDIX 1: Search strategy 
 
 
 
 
 
 
 
 
 
